Inhibition of MK2 in the treatment of cancer
The present invention relates to the discovery that MK2 is highly expressed in cancer tissue and the inhibition of MK2 using an MK2 inhibitor represents a viable approach to the treatment of cancer, including drug resistant cancers, metastatic cancers and recurrent cancers. MK2 inhibitors as described herein may be used alone or in combination with an at least one additional anti-cancer agent for the treatment of cancer.
1. A method of treating cancer in a patient in need comprising administering to said patient an effective amount of a pharmaceutical composition comprising an effective amount of MK2 inhibitor BIO-475863 (CAS-41179-33-3) or PF-3644022 according to the chemical structure:
or
a pharmaceutically acceptable salt or hydrate thereof;
wherein said cancer is colorectal cancer, gastric cancer, head and neck cancer or lung cancer which overexpresses MK2 compared to normal tissue.
2. The method according to claim 1 wherein said cancer is metastatic cancer.
3. The method according to claim 1 wherein said cancer is recurrent cancer.
4. The method according to claim 1 wherein said cancer is colorectal cancer or head and neck cancer.
5. The method according to claim 1 wherein said cancer is colorectal cancer or gastric cancer.
6. The method according to claim 1 wherein said cancer is colorectal cancer or lung cancer.
7. The method according to claim 2 wherein said cancer is colorectal cancer or head and neck cancer.
8. The method according to claim 2 wherein said cancer is colorectal cancer or gastric cancer.
9. The method according to claim 2 wherein said cancer is colorectal cancer or lung cancer.
10. The method according to claim 3 wherein said cancer is colorectal cancer or head and neck cancer.
11. The method according to claim 3 wherein said cancer is colorectal cancer or gastric cancer.
12. The method according to claim 3 wherein said cancer is colorectal cancer or lung cancer.
13. The method according to claim 1 wherein said inhibitor is administered in combination with an additional anticancer agent wherein said additional anticancer agent is 5-fluorouracil (5-FU).
14. The method according to claim 1 which is combined with radiation therapy.
15. The method according to claim 2 which is combined with radiation therapy.
16. The method according to claim 3 which is combined with radiation therapy.
17. The method according to claim 4 which is combined with radiation therapy.
18. The method according to claim 7 which is combined with radiation therapy.
19. The method according to claim 10 which is combined with radiation therapy.
20. The method according to claim 1 wherein said compound is PF-3644022 or a pharmaceutically acceptable salt or hydrate thereof.